Shenyang Xingqi Pharmaceutical Co.,Ltd.

300573

CNE100002DV1

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 2026-01-15			5-day change	1st Jan Change
76.83 ^CNY	+1.56%		+1.78%	+9.30%

Jan. 05	Xingqi Pharmaceutical Gets Nod for Supplementary Application for Atropine Sulfate Eye Drops	MT
Dec. 08	Xingqi Pharmaceutical's 39 Products Stay in China's Insurance Drug Catalogue	MT

Shenyang Xingqi Pharmaceutical Co.,Ltd.(XSEC:300573) added to FTSE All-World Index

Published on 09/22/2024

S&P Capital IQ

Shenyang Xingqi Pharmaceutical Co.,Ltd.

+1.56%

Shenyang Xingqi Pharmaceutical Co.,Ltd.(XSEC:300573) added to FTSE All-World Index (USD)

Latest news about Shenyang Xingqi Pharmaceutical Co.,Ltd.

Jan. 05	Xingqi Pharmaceutical Gets Nod for Supplementary Application for Atropine Sulfate Eye Drops	MT
Dec. 08	Xingqi Pharmaceutical's 39 Products Stay in China's Insurance Drug Catalogue	MT
25-10-28	Shenyang Xingqi Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025	CI
25-10-09	Shenyang Xingqi Pharmaceutical Gets China Clinical Trial Nod for Macular Edema Injection	MT
25-09-16	Shenyang Xingqi Pharmaceutical Co.,Ltd. Approves Interim Cash Dividend on A Shares for 2025, Payable on 24 September 2025	CI
25-08-28	Shenyang Xingqi Pharmaceutical Co.,Ltd. Proposes Interim Cash Dividend for the Year 2025	CI
25-08-27	Shenyang Xingqi Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
25-06-17	Xingqi Pharmaceutical Begins Phase Three Trial for Anesthetic Gel	MT
25-05-30	Xingqi Pharmaceutical Says No Adverse Effects Seen in Phase 1 Eye Drops Trial	MT
25-05-26	Shenyang Xingqi Pharmaceutical Co.,Ltd. announced that it expects to receive CNY 850 million in funding	CI
25-05-15	Shenyang Xingqi Pharmaceutical Co.,Ltd. Approves Final Cash Dividend Plan on A Shares for 2024, Payable on 22 May 2025	CI
25-04-28	Shenyang Xingqi Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
25-04-22	Shenyang Xingqi Pharmaceutical Co.,Ltd. Proposes Final Dividend for the Year 2024	CI
25-04-20	Shenyang Xingqi Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
24-10-28	Shenyang Xingqi Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2024	CI
24-09-22	Shenyang Xingqi Pharmaceutical Co.,Ltd.(XSEC:300573) added to FTSE All-World Index	CI
24-09-18	Shenyang Xingqi Pharmaceutical Co.,Ltd. Approves Interim Cash Dividend for the 2024	CI
24-08-29	Shenyang Xingqi Pharmaceutical Co.,Ltd. Proposes Profit Distribution for First Half of 2024	CI
24-08-28	Shenyang Xingqi Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2024	CI
24-07-25	Xingqi Pharmaceutical Gets Nod to Trial Eye Drops; Shares Up 4%	MT
24-07-24	Xingqi Pharmaceutical Gets Nod to Register Bromfenac Sodium Eye Drops; Shares Down 3%	MT
24-05-21	Space Peptides announced that it has received funding from Humanwell Healthcare Co.,Ltd., Shenyang Xingqi Pharmaceutical Co.,Ltd., Xiamen Furuier Pharmaceutical Co., Ltd., Purple Knight Capital and other investors	CI
24-05-15	Shenyang Xingqi Pharmaceutical Co.,Ltd. Announces Cash Dividend for 2023, Payable May 22, 2024	CI
24-04-26	Shenyang Xingqi Pharmaceutical's Q1 Profit Jumps 80%	MT
24-04-25	Shenyang Xingqi Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Chart Shenyang Xingqi Pharmaceutical Co.,Ltd.

Duration

Period

Chart Shenyang Xingqi Pharmaceutical Co.,Ltd.

300573: Dynamic Chart

SHENYANG XINGQI PHARMACEUTICAL CO., LTD. is a China-based company principally engaged in the research, development, manufacture and distribution of ophthalmic drugs. The Companyâs main products are ophthalmic prescription drugs, including corneal repairing drugs, anti-bacteria drugs, artificial tears, anti-inflammation drugs, anti-allergic drugs, as well as anti-hyperemia & fatigue relief drugs and others. The Company mainly distributes its products within domestic market.

Employees

2,426

Sector

Pharmaceuticals

Calendar

Apr. 21 - Q4 2025 Earnings Release

More about the company